Fingolimod (FTY720) in Acute Demyelinating Optic Neuritis (ADON)

Stopped Discontinuation of this study was based on Novartis decision to discontinue development of fingolimod for the treatment of ADON

Conditions

• Acute Demylelinating Optic Neuritis

Interventions

• DRUG: Fingolimod 0.5mg/daily
• DRUG: Placebo

Sponsor

Novartis Pharmaceuticals